glp 1 agonist uses Another milestone in the evolution of GLP-1-based diabetes therapies GLP-1 Agonists: Using Semaglutide, Tirzepatide,
Description
Kieffer TJ, Habener JF
Microneedle patches are an active area of research
Evidence from dual-energy X-ray absorptiometry and MRI sub-studies suggests that 2545% of total weight loss with semaglutide and tirzepatide may come from reductions in lean body mass
[cited 2025 May 28]
however, there is no mention of the practical application of the use of these medications beyond the purpose of decreasing GI symptoms in the perioperative setting
